InvestorsHub Logo
Followers 62
Posts 6241
Boards Moderated 0
Alias Born 02/19/2019

Re: misiu143 post# 215249

Tuesday, 11/01/2022 11:36:13 PM

Tuesday, November 01, 2022 11:36:13 PM

Post# of 233596
As an actual healthcare provider, Leronliman is nowhere near as effective as other options it seems….. (I’m positive you weren’t one of the small groups who it was tested on as it’s an inventional drug lol). Not useful for Covid, or cancer.

They pumped a subpar / ineffective drug to sell shares. “With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News